Haydar Soydaner Karakuş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Haydar Soydaner Karakuş has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Tuncay Göksel
Department of Pulmonary Medicine, Division of Immunology and Allergy, Laboratory of Occupational & Environmental Respiratory Diseases and Asthma, Faculty of Medicine, Translational Pulmonary Research Center (EgeSAM) Ege University Izmir Turkey
4 shared publications - Ceyda Aldag
Translational Pulmonary Research Center (EgeSAM) Ege University Izmir Türkiye
2 shared publications - Su Özgür
Translational Pulmonary Research Center (EgeSAM), Ege University, Izmir 35100, Türkiye
2 shared publications Ali Veral
Ege University
1 shared publication- Altuğ Koç
Genetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey
1 shared publication - Aslı Tetik Vardarlı
Department of Medical Biology, Faculty of Medicine Ege University Izmir Türkiye
1 shared publication
Latest Publications
- Open Access
- 3 June 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (6) , e70566
Gene Expression Profiling of EGFR , FGFR2 , PIK3CA , PTEN , SMAD4 , STK11 , and TP53 in Cell‐Free RNA From Exhaled Breath Condensate: Diagnostic, Prognostic, and Therapeutic Implications in Advanced Lung Adenocarcinoma
Background: Advanced non‐small cell lung cancer (NSCLC), particularly lung adenocarcinoma, remains a leading cause of cancer‐related mortality. Although molecular profiling has improved disease stratification, most biomarker assays rely on invasive tissue sampling. Exhaled breath condensate (EBC) is an attractive non‐invasive biofluid that may provide clinically relevant molecular information. This study evaluated whether cell‐free RNA (cfRNA) obtained from EBC can capture diagnostically and prognostically informative gene‐expression changes in advanced lung adenocarcinoma. Methods: In this prospective study, 40 patients with histologically confirmed stage IIIB–IV lung adenocarcinoma and 20 healthy controls were enrolled. EBC samples were collected from all participants, and plasma samples were obtained from a subgroup of 10 patients and 10 controls. Expression of EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, and TP53 was quantified by RT‐qPCR and normalized to GAPDH using the 2 −ΔΔCT method. Receiver operating characteristic (ROC) analysis, correlation testing, and Kaplan–Meier survival analysis were performed. Results: The most clinically relevant findings were observed for PIK3CA , FGFR2 , and EGFR . In EBC, PIK3CA emerged as the only gene with significant diagnostic performance for distinguishing patients from healthy controls (AUC = 0.8522; sensitivity 81.58%; specificity 76.92%). In survival analyses, high FGFR2 and high PIK3CA expression were associated with significantly shorter overall survival, supporting their prognostic relevance. In treatment‐stratified analysis, low EGFR expression was associated with longer survival in patients receiving chemotherapy alone, suggesting potential predictive value in this subgroup. In plasma, PIK3CA was upregulated approximately five‐fold, whereas EGFR was downregulated approximately five‐fold. Notably, EGFR expression showed a strong positive correlation between EBC and plasma ( R 2 = 0.7849, p = 0.0006), indicating cross‐matrix consistency for this marker. By contrast, alterations in PTEN , TP53 , and SMAD4 should be considered exploratory, as they showed differential expression but lacked comparable diagnostic, prognostic, or treatment‐associated strength. Conclusions: EBC‐based cfRNA profiling provides a feasible, non‐invasive approach for molecular characterization of advanced lung adenocarcinoma. Among the genes examined, PIK3CA showed the strongest diagnostic signal, FGFR2 demonstrated prognostic significance, and EGFR showed the clearest cross‐sample concordance and treatment‐associated relevance. Larger independent validation studies are required before clinical implementation.
- 3 June 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (6) , e70566
Open AccessGene Expression Profiling of EGFR , FGFR2 , PIK3CA , PTEN , SMAD4 , STK11 , and TP53 in Cell‐Free RNA From Exhaled Breath Condensate: Diagnostic, Prognostic, and Therapeutic Implications in Advanced Lung Adenocarcinoma
Background: Advanced non‐small cell lung cancer (NSCLC), particularly lung adenocarcinoma, remains a leading cause of cancer‐related mortality. Although molecular profiling has improved disease stratification, most biomarker assays rely on invasive tissue sampling. Exhaled breath condensate (EBC) is an attractive non‐invasive biofluid that may provide clinically relevant molecular information. This study evaluated whether cell‐free RNA (cfRNA) obtained from EBC can capture diagnostically and prognostically informative gene‐expression changes in advanced lung adenocarcinoma. Methods: In this prospective study, 40 patients with histologically confirmed stage IIIB–IV lung adenocarcinoma and 20 healthy controls were enrolled. EBC samples were collected from all participants, and plasma samples were obtained from a subgroup of 10 patients and 10 controls. Expression of EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, and TP53 was quantified by RT‐qPCR and normalized to GAPDH using the 2 −ΔΔCT method. Receiver operating characteristic (ROC) analysis, correlation testing, and Kaplan–Meier survival analysis were performed. Results: The most clinically relevant findings were observed for PIK3CA , FGFR2 , and EGFR . In EBC, PIK3CA emerged as the only gene with significant diagnostic performance for distinguishing patients from healthy controls (AUC = 0.8522; sensitivity 81.58%; specificity 76.92%). In survival analyses, high FGFR2 and high PIK3CA expression were associated with significantly shorter overall survival, supporting their prognostic relevance. In treatment‐stratified analysis, low EGFR expression was associated with longer survival in patients receiving chemotherapy alone, suggesting potential predictive value in this subgroup. In plasma, PIK3CA was upregulated approximately five‐fold, whereas EGFR was downregulated approximately five‐fold. Notably, EGFR expression showed a strong positive correlation between EBC and plasma ( R 2 = 0.7849, p = 0.0006), indicating cross‐matrix consistency for this marker. By contrast, alterations in PTEN , TP53 , and SMAD4 should be considered exploratory, as they showed differential expression but lacked comparable diagnostic, prognostic, or treatment‐associated strength. Conclusions: EBC‐based cfRNA profiling provides a feasible, non‐invasive approach for molecular characterization of advanced lung adenocarcinoma. Among the genes examined, PIK3CA showed the strongest diagnostic signal, FGFR2 demonstrated prognostic significance, and EGFR showed the clearest cross‐sample concordance and treatment‐associated relevance. Larger independent validation studies are required before clinical implementation.
- Open Access
- 18 September 2025
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 27 (1) , 47-56
Update: The New 9th Edition TNM Classification for Lung Cancer Is Now in Use
Update: The New 9th Edition TNM Classification for Lung Cancer Is Now in Use - Thoracic Research and Practice
- 18 September 2025
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 27 (1) , 47-56
Open AccessUpdate: The New 9th Edition TNM Classification for Lung Cancer Is Now in Use
Update: The New 9th Edition TNM Classification for Lung Cancer Is Now in Use - Thoracic Research and Practice
- Open Access
- 31 January 2025
- Published by Dokuz Eyul Universitesi Saglik Bilimleri Enstitusu in Journal of Basic and Clinical Health Sciences
- Vol. 9 (1) , 205-211
Investigation of Epidermal Growth Factor Receptor Pathway Related, Exosomal miRNAs in Non-Small Cell Lung Cancer Cases
Background and Purpose: Recently, the “Epidermal Growth Factor Receptor” gene and its related pathways are potential targets in precision medicine for “Non-Small Cell Lung Cancer” cases. The presented study is a proof of concept study, which utilizes exosomal miRNAs as an easy and cheap liquid biopsy approach. We aim to investigate, 4 exosomal miRNAs: miR-30b, miR-30c, miR-221-3p, miR-22-3p; and miR-1288 as control. They are defined in the literature previously. Methods: Thirty-six samples from distinct Non-Small Cell Lung Cancer cases are analyzed. Exosomes are extracted from the plasma of the patients; miRNA isolation, cDNA synthesis, and real-time quantitative polymerase chain reactions are done and ∆/∆ Ct method is used for relative quantification. Results: The control miR1288 is expressed in all of the samples except one. The two miRNA targets miR-30c and miR-22-3p produced polymerase chain reaction curves successfully. The remaining two miRNAs (miR-30b, miR-221-3p) produce weak polymerase chain reaction curves. Conclusion: miR-30b, miR-221-3p, miR-30c, and miR-22-3p are reported to be associated with lung cancer previously, but they have not been studied in a patient series before. In our study, the exosomal miR-30c, and miR-22-3p are successfully derived from the plasma of cancer cases and they could be potential biomarkers.
- 31 January 2025
- Published by Dokuz Eyul Universitesi Saglik Bilimleri Enstitusu in Journal of Basic and Clinical Health Sciences
- Vol. 9 (1) , 205-211
Open AccessInvestigation of Epidermal Growth Factor Receptor Pathway Related, Exosomal miRNAs in Non-Small Cell Lung Cancer Cases
Background and Purpose: Recently, the “Epidermal Growth Factor Receptor” gene and its related pathways are potential targets in precision medicine for “Non-Small Cell Lung Cancer” cases. The presented study is a proof of concept study, which utilizes exosomal miRNAs as an easy and cheap liquid biopsy approach. We aim to investigate, 4 exosomal miRNAs: miR-30b, miR-30c, miR-221-3p, miR-22-3p; and miR-1288 as control. They are defined in the literature previously. Methods: Thirty-six samples from distinct Non-Small Cell Lung Cancer cases are analyzed. Exosomes are extracted from the plasma of the patients; miRNA isolation, cDNA synthesis, and real-time quantitative polymerase chain reactions are done and ∆/∆ Ct method is used for relative quantification. Results: The control miR1288 is expressed in all of the samples except one. The two miRNA targets miR-30c and miR-22-3p produced polymerase chain reaction curves successfully. The remaining two miRNAs (miR-30b, miR-221-3p) produce weak polymerase chain reaction curves. Conclusion: miR-30b, miR-221-3p, miR-30c, and miR-22-3p are reported to be associated with lung cancer previously, but they have not been studied in a patient series before. In our study, the exosomal miR-30c, and miR-22-3p are successfully derived from the plasma of cancer cases and they could be potential biomarkers.
- Open Access
- 23 April 2022
- Published by Adiyaman University in Adıyaman Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 8 (1) , 17-26
Symptom clusters in patients with lung cancer patients receiving chemotherapy
Aim: The aim was to identify symptoms experienced by patients with lung cancer who had received chemotherapy and to determine the symptom clusters.Materials and Methods: This was a descriptive and cross-sectional study. A Patient Presentation Form, the ECOG Performance Scale, and the Memorial Symptom Assessment Scale were used. The data were collected between September 2016 and June 2017. The sample of the study consisted of 100 patients who met the selection criteria.Results: When the prevalence of the symptoms experienced by the patients was examined, the most common complaints were lack of energy (82%), loss of appetite (71%), change in taste of food (62%), anxiety and feeling irritable (69%). The most common symptoms were weakness (8%), loss of appetite (14%), anxiety (20%) and feeling sad (28%).Conclusion: When the occurrence and severity ratings were examined, the symptoms could be placed into five groups: the gastrointestinal system cluster, the psychology cluster, the respiratory cluster, the neurology cluster, and the cluster of skin changes. The symptoms of lung cancer patients interact with each other and should be managed with appropriate interventions. Moreover, health professionals’ awareness of symptom management should be improved.
- 23 April 2022
- Published by Adiyaman University in Adıyaman Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 8 (1) , 17-26
Open AccessSymptom clusters in patients with lung cancer patients receiving chemotherapy
Aim: The aim was to identify symptoms experienced by patients with lung cancer who had received chemotherapy and to determine the symptom clusters.Materials and Methods: This was a descriptive and cross-sectional study. A Patient Presentation Form, the ECOG Performance Scale, and the Memorial Symptom Assessment Scale were used. The data were collected between September 2016 and June 2017. The sample of the study consisted of 100 patients who met the selection criteria.Results: When the prevalence of the symptoms experienced by the patients was examined, the most common complaints were lack of energy (82%), loss of appetite (71%), change in taste of food (62%), anxiety and feeling irritable (69%). The most common symptoms were weakness (8%), loss of appetite (14%), anxiety (20%) and feeling sad (28%).Conclusion: When the occurrence and severity ratings were examined, the symptoms could be placed into five groups: the gastrointestinal system cluster, the psychology cluster, the respiratory cluster, the neurology cluster, and the cluster of skin changes. The symptoms of lung cancer patients interact with each other and should be managed with appropriate interventions. Moreover, health professionals’ awareness of symptom management should be improved.
- 30 June 2021
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 8 (2) , 358-365
Magnetic Catheter Navigation Systems
Son 10 yılda biyopsi ve tanı işlemleri esnasında doktor vasıtasıyla manuel ve robotik olarak gerçekleştirilen endoskopi, kolonoskopi, bronkoskopi gibi işlemlerde oluşabilecek komplikasyonları en aza indirmeye yarayacak sistemlerin üzerine çalışılmaya başlanmıştır. Bu sistemlerin en önemli özelliği yönlendirilecek kateterin manyetik özelliğe sahip olması ve elektromanyetik sistemler ile kateterin temassız bir şekilde yönlendirilmesidir. Bunun yanı sıra tedaviye yönelik başka işlemler için de manyetik özelliğe sahip kapsül, robot, ilaç taşıma sistemleri vb. araçlar geliştirilmektedir. Bu araçların yönlendirilmesi de bahsedilen sistemler aracılığıyla temassız bir şekilde gerçekleştirilebilmektedir. Bu çalışmada temassız yönlendirmeyi sağlayan manyetik kateter navigasyon sistemleri hakkında bilgi verilmektedir.
- 30 June 2021
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 8 (2) , 358-365
Magnetic Catheter Navigation Systems
Son 10 yılda biyopsi ve tanı işlemleri esnasında doktor vasıtasıyla manuel ve robotik olarak gerçekleştirilen endoskopi, kolonoskopi, bronkoskopi gibi işlemlerde oluşabilecek komplikasyonları en aza indirmeye yarayacak sistemlerin üzerine çalışılmaya başlanmıştır. Bu sistemlerin en önemli özelliği yönlendirilecek kateterin manyetik özelliğe sahip olması ve elektromanyetik sistemler ile kateterin temassız bir şekilde yönlendirilmesidir. Bunun yanı sıra tedaviye yönelik başka işlemler için de manyetik özelliğe sahip kapsül, robot, ilaç taşıma sistemleri vb. araçlar geliştirilmektedir. Bu araçların yönlendirilmesi de bahsedilen sistemler aracılığıyla temassız bir şekilde gerçekleştirilebilmektedir. Bu çalışmada temassız yönlendirmeyi sağlayan manyetik kateter navigasyon sistemleri hakkında bilgi verilmektedir.
- 24 April 2015
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 49 (2) , 188-200
Prevalence and Seasonal Distribution of Respiratory Viruses in Patients with Acute Respiratory Tract Infections, 2002-2014
<%=header_description %> <%=header_description %>
- 24 April 2015
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 49 (2) , 188-200
Prevalence and Seasonal Distribution of Respiratory Viruses in Patients with Acute Respiratory Tract Infections, 2002-2014
<%=header_description %> <%=header_description %>
- 25 July 2014
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (2) , 395-404
Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations
Chemotherapy is one of the main treatments for lung cancer, and in these patients, discontinuation of treatment due to uncontrollable hypersensitivity reactions (HSRs) is an important problem. To determine the frequency of HSRs during chemotherapy and to review current approaches. We did a cross sectional study in patients undergoing chemotherapy for lung cancer in a reference chemotherapy unit from January 2012 to January 2013. Patients who developed immediate-HSRs or delayed-HSRs to chemotherapeutics and gave consent were included into study. The effectiveness of a standardised 12-step “rapid drug desensitisation” (RDD) procedure was investigated in patients with immediate-HSRs. In total, 1,099 cycles of chemotherapy were administered to 292 patients in 1 year. We observed ten HSRs, during ten cycles in ten patients (~3 % of the patients). Two HSRs were delayed-type, eight were immediate-type at grade 1–3. Of those with immediate-type HSR, five patients with grade 2–3, and additional two referred patients with grade 4 HSRs were successfully given their culprit drug in 35 cycles of chemotherapy with 12-step or modified 20-step RDD protocol. HSRs to chemotherapeutics are not so rare. Premedication alone does not prevent such reactions. The results of RDD treatment look promising for continuing treatment with the culprit chemotherapeutic agent.
- 25 July 2014
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (2) , 395-404
Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations
Chemotherapy is one of the main treatments for lung cancer, and in these patients, discontinuation of treatment due to uncontrollable hypersensitivity reactions (HSRs) is an important problem. To determine the frequency of HSRs during chemotherapy and to review current approaches. We did a cross sectional study in patients undergoing chemotherapy for lung cancer in a reference chemotherapy unit from January 2012 to January 2013. Patients who developed immediate-HSRs or delayed-HSRs to chemotherapeutics and gave consent were included into study. The effectiveness of a standardised 12-step “rapid drug desensitisation” (RDD) procedure was investigated in patients with immediate-HSRs. In total, 1,099 cycles of chemotherapy were administered to 292 patients in 1 year. We observed ten HSRs, during ten cycles in ten patients (~3 % of the patients). Two HSRs were delayed-type, eight were immediate-type at grade 1–3. Of those with immediate-type HSR, five patients with grade 2–3, and additional two referred patients with grade 4 HSRs were successfully given their culprit drug in 35 cycles of chemotherapy with 12-step or modified 20-step RDD protocol. HSRs to chemotherapeutics are not so rare. Premedication alone does not prevent such reactions. The results of RDD treatment look promising for continuing treatment with the culprit chemotherapeutic agent.
- 1 April 2002
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 16 (2) , 103-108
The role of Tc-99m sestamibi imaging in predicting clinical response to chemotherapy in lung cancer
- 1 April 2002
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 16 (2) , 103-108
The role of Tc-99m sestamibi imaging in predicting clinical response to chemotherapy in lung cancer